Q2 2024 EPS Estimates for UroGen Pharma Ltd. Raised by Analyst (NASDAQ:URGN)

UroGen Pharma Ltd. (NASDAQ:URGN) – Analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for UroGen Pharma in a research report issued on Monday, July 1st. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.77) per share for the quarter, up from their prior forecast of ($0.83). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q3 2024 earnings at ($0.75) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($3.16) EPS, Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.61) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.72) EPS.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The firm had revenue of $18.78 million during the quarter, compared to analyst estimates of $20.73 million.

URGN has been the topic of several other research reports. Oppenheimer increased their target price on UroGen Pharma from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, June 14th. LADENBURG THALM/SH SH upped their price objective on shares of UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a research note on Friday, June 14th.

UroGen Pharma Price Performance

NASDAQ:URGN opened at $15.01 on Wednesday. The firm has a market capitalization of $351.98 million, a PE ratio of -4.41 and a beta of 1.12. The business’s fifty day moving average price is $14.42 and its 200 day moving average price is $15.26. UroGen Pharma has a 12 month low of $8.69 and a 12 month high of $24.13.

Institutional Trading of UroGen Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in UroGen Pharma by 361.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company’s stock worth $54,000 after acquiring an additional 2,801 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of UroGen Pharma by 31.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 4,955 shares of the company’s stock valued at $74,000 after purchasing an additional 1,191 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $131,000. Federated Hermes Inc. acquired a new position in shares of UroGen Pharma in the 3rd quarter valued at $184,000. Finally, Sierra Summit Advisors LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $218,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at UroGen Pharma

In other news, insider Mark Schoenberg sold 5,153 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $13.08, for a total transaction of $67,401.24. Following the completion of the transaction, the insider now directly owns 144,284 shares of the company’s stock, valued at approximately $1,887,234.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 11.13% of the stock is currently owned by corporate insiders.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.